MOC Stock Overview
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.
Price History & Performance
|Historical stock prices|
|Current Share Price||zł14.40|
|52 Week High||zł44.45|
|52 Week Low||zł12.04|
|1 Month Change||-8.86%|
|3 Month Change||-8.28%|
|1 Year Change||-67.12%|
|3 Year Change||20.50%|
|5 Year Change||n/a|
|Change since IPO||-50.35%|
Recent News & Updates
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|MOC||PL Pharmaceuticals||PL Market|
Return vs Industry: MOC underperformed the Polish Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: MOC underperformed the Polish Market which returned -33.1% over the past year.
|MOC Average Weekly Movement||9.0%|
|Pharmaceuticals Industry Average Movement||5.5%|
|Market Average Movement||6.1%|
|10% most volatile stocks in PL Market||11.7%|
|10% least volatile stocks in PL Market||3.8%|
Stable Share Price: MOC is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MOC's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022.
Molecure Fundamentals Summary
|MOC fundamental statistics|
Is MOC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MOC income statement (TTM)|
|Cost of Revenue||zł2.20m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Sep 29, 2022
|Earnings per share (EPS)||-1.05|
|Net Profit Margin||-757.47%|
How did MOC perform over the long term?See historical performance and comparison
Is MOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MOC?
Other financial metrics that can be useful for relative valuation.
|What is MOC's n/a Ratio?|
Price to Book Ratio vs Peers
How does MOC's PB Ratio compare to its peers?
|MOC PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
CLN Celon Pharma
CBD Cannabis Poland
Price-To-Book vs Peers: MOC is good value based on its Price-To-Book Ratio (1.5x) compared to the peer average (11.5x).
Price to Earnings Ratio vs Industry
How does MOC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Book vs Industry: MOC is good value based on its Price-To-Book Ratio (1.5x) compared to the European Pharmaceuticals industry average (2x)
Price to Book Ratio vs Fair Ratio
What is MOC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.5x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate MOC's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MOC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MOC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Molecure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Molecure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Molecure performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MOC is currently unprofitable.
Growing Profit Margin: MOC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MOC is unprofitable, but has reduced losses over the past 5 years at a rate of 48.5% per year.
Accelerating Growth: Unable to compare MOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Return on Equity
High ROE: MOC has a negative Return on Equity (-10.69%), as it is currently unprofitable.
Discover strong past performing companies
How is Molecure's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MOC's short term assets (PLN108.5M) exceed its short term liabilities (PLN5.3M).
Long Term Liabilities: MOC's short term assets (PLN108.5M) exceed its long term liabilities (PLN4.3M).
Debt to Equity History and Analysis
Debt Level: MOC is debt free.
Reducing Debt: MOC had no debt 5 years ago.
Debt Coverage: MOC has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MOC has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Molecure current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Molecure Dividend Yield vs Market|
|Market Bottom 25% (PL)||3.1%|
|Market Top 25% (PL)||9.6%|
|Industry Average (Pharmaceuticals)||2.9%|
|Analyst forecast in 3 Years (Molecure)||n/a|
Notable Dividend: Unable to evaluate MOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MOC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MOC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MOC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...
Experienced Management: MOC's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: MOC's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Molecure S.A.'s employee growth, exchange listings and data sources
- Name: Molecure S.A.
- Ticker: MOC
- Exchange: WSE
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł202.032m
- Shares outstanding: 14.03m
- Website: https://molecure.com
Number of Employees
- Molecure S.A.
- Zwirki i Wigury 101
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MOC||WSE (Warsaw Stock Exchange)||Yes||Bearer Shares||PL||PLN||Apr 2018|
|1B1||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Apr 2018|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.